Zydus Lifesciences (ZYDUSLIFE) — Financial Results

Zydus Lifesciences reported Q3 FY26 consolidated revenues of ₹68.6 billion, up 30% YoY, with EBITDA of ₹18.2 billion (up 31% YoY) and adjusted net profit of ₹11.1 billion (up 9% YoY). North America pharma grew 16% YoY to ₹28 billion, while International Markets formulations surged 38% YoY. Consumer Wellness revenues doubled to ₹9.6 billion following acquisitions. The company secured USFDA approval for Zycubo, launched oncology product BEIZRAY, filed 18 ANDAs with 8 approvals, and launched 4 new US generics despite challenging pricing.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"How does this financial results affect Zydus Lifesciences Limited's outlook?" "What did Zydus Lifesciences Limited announce on 15 February 2026?" "Is this positive or negative for ZYDUSLIFE?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 15 February 2026

BEL Bharat Electronics Limited Board Meeting

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.